In Utero SARS-CoV-2 Exposure
Conditions
Keywords
metabolic disease, cardiovascular disease
Brief summary
Since its initial outbreak in late 2019, coronavirus disease 2019 (COVID-19) caused by the novel coronavirus SARS-CoV-2 has ravaged the globe, causing illness characterized by inflammation and impaired oxygen levels. As a particularly vulnerable group, pregnant women have had a heightened prevalence and severity of infection. In this context, a new population of children has emerged who were exposed to maternal COVID-19 in the womb. As maternal diseases during pregnancy may impact the health of offspring over the life course, health outcomes among these individuals must be urgently evaluated. In the current study, the investigators will leverage a perinatal biorepository comprised of pregnant women with and without COVID-19 to delineate the metabolic and cardiovascular risk profiles of these offspring. This work stands to benefit the burgeoning population of children exposed to COVID-19 in the womb and to deepen the mechanistic understanding of developmental origins of cardiometabolic disease with respect to maternal infections.
Interventions
OTHERIn Utero Exposure to SARS-CoV-2
Born to mother with SARS-CoV-2 infection during pregnancy
Sponsors
Massachusetts General Hospital
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
9 Months to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Mother with or without prenatal COVID-19 who was enrolled in the MGH COVID-19 Perinatal Biorepository and her child (9-24 months old)
Exclusion criteria
* Child with any history of documented COVID-19 * Mother who received the COVID-19 vaccine during pregnancy with her child * Significant chronic illness in mother or child judged by the investigator to represent a contraindication to study participation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Aortic pulse-wave velocity | Baseline |
Secondary
| Measure | Time frame |
|---|---|
| Weight-for-length z-score | Baseline |
| Systolic and diastolic blood pressure | Baseline |
| Beta index of aortic stiffness using echocardiogram | Baseline |
| Aortic intima-media thickness using echocardiogram | Baseline |
| Skinfold thicknesses (subscapular, triceps) | Baseline |
| Urinary angiotensin converting enzyme (ACE) levels | Baseline |
| Left ventricular mass | Baseline |
| Left ventricular dimensions | Baseline |
| Urinary angiotensin peptide levels | Baseline |
Countries
United States
Outcome results
None listed